

University of Groningen

Kinase activity profiling in pediatric brain tumors

Sikkema, Arend Hendrik

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2011

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Sikkema, A. H. (2011). *Kinase activity profiling in pediatric brain tumors: A novel strategy for the identification of druggable targets*. [Thesis fully internal (DIV), University of Groningen]. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Centrale	U
Medische	M
Bibliotheek	S
Groningen	G

STELLINGEN

Behorende bij het proefschrift

Kinase activity profiling in pediatric brain tumors: a novel strategy for the identification of druggable targets.

1. Generating a network view on kinase activity will provide critical perspectives on cancer therapy, either by allowing the selection of accurate targets or to devise the most optimal therapy for the individual patient. *(This thesis)*
2. Combining the old SRC (Surgery, Radiotherapy, Chemotherapy) with the new Src (sarcoma tyrosine kinase inhibitors) holds great promise for the treatment of pediatric brain tumors. *(Adapted from de Groot J., Milano V., et al. J Neurooncol)*
3. Tyrosine kinase activity screening allows the generation of clinically relevant kinase activity profiles enabling rapid screening for potential druggable targets in a broad range of malignancies. *(This thesis)*
4. Variability in substrate motif recognition explains the apparent contradictory interpretations of the forces that drive kinase substrate selection. *(This thesis)*
5. Insufficient ways to predict the efficacy of inhibiting specific kinase activity gives rise to a discrepancy between the evaluation of aberrant cell signaling and the currently available ensemble of highly specific targeted treatment strategies. *(This thesis)*
6. Counteracting effects in response to activation of different Eph receptors reflects a tightly controlled balance in relative expression of the various receptors, which is ultimately decisive for the phenotype. *(This thesis)*
7. Phos-Tag SDS-PAGE allows simultaneous assessment of protein phosphorylation at multiple phosphorylation sites. *(This thesis)*
8. Ofschoon notoir pathologisch; alcohol blijft onontbeerlijk in de pathologie.
9. To regret growing older is to regret a privilege denied to many. *(Unknown)*
10. Curiosity is the essence of human existence. *(Eugene A Cernan)*

Arend H. Sikkema
2 november 2011